Bile acids are soluble derivatives of cholesterol produced in the liver that subsequently
undergo bacterial transformation yielding a diverse array of metabolites. The bulk of bile …

Abstract Systems medicine has a mechanism-based rather than a symptom-or organ-based
approach to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In …

Metabolic reprogramming is a hallmark of cancer. However, systematic characterizations of
metabolites in triple-negative breast cancer (TNBC) are still lacking. Our study profiled the …

The trillions of microorganisms in the gut microbiome have attracted much attention recently
owing to their sophisticated and widespread impacts on numerous aspects of host …

In solid tumours, cancer cells exist within hypoxic microenvironments, and their metabolic
adaptation to this hypoxia is driven by HIF-1 transcription factor, which is overexpressed in a …

Current standard-of-care (SOC) therapy for breast cancer includes targeted therapies such
as endocrine therapy for estrogen receptor-alpha (ERα) positive; anti-HER2 monoclonal …

Metabolomics holds the promise as a new technology to diagnose highly heterogeneous
diseases. Conventionally, metabolomics data analysis for diagnosis is done using various …

The ability of a cancer cell to develop resistance to anoikis, a programmed cell death
process triggered by substratum detachment, is a critical step in the metastatic cascade …

Breast cancer is a leading cause of death among women worldwide. Dysbiosis, an aberrant
composition of the microbiome, characterizes breast cancer. In this review we discuss the …

During tumorigenesis, breast tumour cells undergo metabolic reprogramming, which
generally includes enhanced glycolysis, tricarboxylic acid cycle activity, glutaminolysis and …